Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose alemtuzumab for severe kidney transplant rejection
NL-OMON53625Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of alemtuzumab in kidney allograft rejection, sponsored by Erasmus MC. Primary endpoint: T lymphocyte repopulation at 6 months. Started Nov 2023; status: recruiting.
02
Drugs
alemtuzumab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON53625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53625.